Peroneal Neuropathies

XP Health, a company developing a digital-first vision benefits platform, raised $17.1 million in a Series A funding round led by HC9 Ventures, Valor Capital Group and ManchesterStory. Additional investors include Core Innovation Capital, GSR Ventures, Canvas Ventures, Plug and Play, CameronVC, Ken Goulet, Kevin Hill, Jeff Epstein and Brett Rochkind. This recent funding round followed a $5.5 million raise in 2021. "This round of funding enables us to strengthen the platform’s functionality and provide a stellar consumer experience in the most affordable way to employers, insurance carriers and employees," Antonio Moraes, cofounder and CEO of XP Health, said in a statement. "We have a game-changing offering for how people access and experience employee benefits – with an ultimate goal to positively impact hundreds of millions of lives through high-quality, accessible and affordable health benefits." Lung-health company Optellum announced closing a $14 million Series A funding round led by U.K. venture capital firm Mercia with participation from U.S. firms Intuitive Ventures and Black Opal. Its Virtual Nodule Clinic software is used to track, assess and characterize nodules in the lungs. The company attained FDA clearance in the U.S., CE-MDR in the European Union, and UKCA in the United Kingdom for the platform. A CE mark certificate (CE-MDR) is needed to commercialize medical devices in the EU. The U.K. Conformity Assessed marking indicates a product conforms with applicable requirements to be sold in Great Britain. "[Virtual Nodule Clinic] can help physicians identify and track at-risk patients, and optimally diagnose the signs of lung cancer early — so treatment can be started sooner for patients with tumors, and to minimize invasive procedures such as biopsies on benign lesions," the company said in a press release. The company behind the Cionic Neural Sleeve received $12.5 million in a Series A funding led by BlueRun Ventures, with participation from EPIC Ventures, LDV Capital, Caffeinated Capital and JobsOhio Growth Capital Fund. This round of funding follows Cionic Neural Sleeve’s FDA clearance in early 2022. The leg-worn device provides electrical stimulation so people with foot drop and muscle weakness can walk more easily. Cionic has so far received $23 million to build its platform focused on human mobility. The new round of funds will help the company expand manufacturing and delivery of its mobility technology, and accelerate research trials and commercialization of its products for new indications. "Forward-looking investors realize that we need to take action today, and we are proud to be backed by a group of investors who recognize the need for better solutions and have joined us in our mission to redefine human mobility," Cionic founder and CEO Jeremiah Robison said in a statement. Kaleidoscope, a cloud-based research platform that maps data usage by R&D teams, solidified a $6 million seed financing round. It was co-led by Hummingbird Ventures and Dimension, with participation from SV Angel, Hawktail, Caffeinated Capital and individual investors. The funding will help the company further develop the platform’s product and expand the company’s team, especially with software engineers. "The way people work in research is changing. Kaleidoscope bridges the gap between teams on a platform that integrates with other software tools. The funding will enable us to deliver the best product and user experience to make research more collaborative, reproducible and scalable," Bogdan Knezevic, CEO and cofounder of Kaleidoscope, said in a statement. Arcascope, a health technology company focusing on circadian rhythm disruption, announced it closed a $2.85 million seed round. The round was led by Supermoon Capital, with participation from New Dominion Angels, Inflect Health, Inception Health, the Accelerate Blue Fund, the Monroe Brown Seed Fund, AIoT Health, HealthX Ventures and other angel investors. The company is launching a circadian rhythm management platform, currently accessible via the smartphone app, Shift, to address the sleep needs of shift workers. Surge, a company developing machine learning technology to decode a patient’s blood sample to forecast the risk of postoperative complications, announces a $2.6 million round co-led by HCVC and Boutique Venture Partners, with participation by Nicolas Godin. The company also obtained the exclusive license to the patented postoperative complication prediction technology from Stanford University, which includes 10+ years of research on surgical risk prediction. Surge also signed a research agreement with Stanford intending to develop biotech innovations. This new round of funding will support the company in developing its team further and conducting clinical studies with more hospitals.

Increasing demand for improving patient outcomes and reducing surgery time is accelerating automated solutions adoption, thus propelling the market forward Fact.MR, Rockville MD: Market research company Fact.MR’s ongoing skeletal deformation correction market forecasts a positive outlook 2021, as orthopedic surgical procedures resume in the aftermath of the COVID-19 pandemic induced elective surgical postponement. While recovery is expected to be gradual, increasing footfalls in forthcoming months shall restore projections to pre-pandemic levels, eventually reaching new echelons in the long-term forecast period. The market is slated to be propelled amidst the increasing burden of osteoporosis and other skeletal disorders. As per data published during the World Osteoporosis Day 2020, over half of all individuals globally aged above 50 are likely to develop weak bones, with vertebral spine and limb fractures being most frequent. Consequently, healthcare providers are incorporating advanced treatment solutions, widening growth prospects. Manufacturers are embracing automated surgical solutions, laying emphasis on computer aided surgical procedures. Players such as da Vinci Surgery have made significant strides in the head & neck surgical domains. The company offers a surgeon console, offering a close up 3D view of the patient’s anatomy. Also, the patient cart and vision cart accompanying the system makes communication between components possible, streamlining surgical operations. “Growing emphasis on precision based surgeries to improve patient outcomes is paving way for automated skeletal deformation correction systems deployment, prompting manufacturers to enhance their research and development capabilities,” says the Fact.MR analyst. Request a report sample to gain comprehensive insights at Key Takeaways from Fact.MR’s Skeletal Deformation Correction Study By procedure type, limb reconstruction procedures shall gain ground in forthcoming years Hospitals to remain primary skeletal deformation correction points, orthopedic surgical centers to acquire popularity US to generate lucrative growth prospects, with manufacturers specializing in porous polyethylene implants Growing scope of arthroplasty procedures amid high prevalence of osteoarthritis and rheumatoid arthritis to spur sales across the UK Widespread presence of orthopedic surgical equipment manufacturers to broaden growth prospects across Germany India to generate revenue pockets amid increasing number of surgical procedures due to widespread rickets prevalence Skeletal Deformation Correction Market- Prominent Drivers Increasing demand for minimally invasive procedures to reduce patient trauma is fueling developments such as scoliosis, thus augmenting growth Manufacturers are increasing their foray across automated surgical procedures, consistent with the rising demand for automated procedures Increasing research studies to ascertain the role of bone stem cells in correcting skeletal deformities to open up new growth avenues Skeletal Deformation Correction Market- Key Restraints Growing onset of transient peroneal nerve palsies in the aftermath of total knee arthroplasty in skeletal dysplasia to pose significant challenges to market growth Unintended surgical injuries and prosthetic losses in post-operative settings are likely to restrain expansion Discover more about the skeletal deformation correction market with figures, data tables and the table of contents. You will also find detailed market segmentation on Competitive Landscape Zimmer Biomet, Johnson & Johnson Services Inc., Smith & Nephew Plc., K2M Group Holdings, Orthofix Medical Inc., Stryker Corporation, Arthrex Inc., Sonoma Orthopedic Products Inc., Wright Medical Group Inc., ONKOS SURGICAL and Hanger Inc. are some prominent manufacturers operating in the global skeletal deformation correction market. Key manufacturers are focusing on strategic collaborations to further their product outreach. In February 2021, Johnson & Johnson Services Inc.’s healthcare products subsidiary, DePuy Synthes, inked an agreement with Expanding Innovations Inc. to further the development of its X-Pac Expandable Lumbar Cage System to expand its operations within the minimally invasive spinal surgeries. Additionally, new product launches also constitute an important expansion strategy. In 2017, Orthofix Medical Inc. unveiled its JuniOrtho product portfolio to introduce extremity fixation solutions for pediatric patients. The platform also offers resources and tools for families through its website to educate patients about the importance of correcting orthopedic deformities. More Insights on the Skeletal Deformation Correction Market In its latest report, Fact.MR offers unbiased analysis of the global skeletal deformation correction market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of procedure type (osteotomy, limb reconstruction, arthrodesis, arthroplasty, vertebral column resection and others) and end user (hospital, ambulatory surgical centers and orthopedic surgical centers) across seven regions (North America, Latin America, Europe, CIS & Russia, Japan, APEJ and Middle East & Africa) Request more information about Report Methodology About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Sudip Saha US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that in the second half of 2017 it plans to initiate a Phase 2 clinical trial of ACE-083, the Company’s locally acting muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT), one of the most common inherited neurologic diseases leading to focal muscle weakness. “We are pleased to expand our clinical development program for ACE-083 into a second neuromuscular disease” “We are pleased to expand our clinical development program for ACE-083 into a second neuromuscular disease,” said Matthew Sherman, M.D., Executive Vice President and Chief Medical Officer at Acceleron. “We believe ACE-083 can strengthen the targeted leg muscles in CMT patients and thereby improve their ability to walk and avoid falls. We look forward to hosting the educational webinar during which we will describe CMT and our enthusiasm for the potential of ACE-083 to address the substantial unmet medical needs of patients.” CMT Phase 2 Trial Design The two-part Phase 2 clinical trial is designed to evaluate ACE-083 in CMT patients with muscle weakness in the tibialis anterior (TA), a muscle in the lower leg involved in foot dorsiflexion (raising the foot at the ankle). Part 1 is an open-label, dose-escalation phase of the study, with ACE-083 administered by injection into the TA muscle once every 3 weeks in up to 18 patients to evaluate safety and increases in muscle volume over a 3-month treatment period. Part 2 is a randomized, double-blind, placebo-controlled phase using the optimal dose level selected in Part 1. A total of 24 patients will be randomized in Part 2 to receive either placebo or ACE-083 and will be evaluated for increases in muscle volume, strength, function and safety over a 3-month treatment period. Webinar The Company will host an educational webinar providing an overview of CMT and a detailed review of the Company's Phase 2 clinical trial. The webinar will be led by neuromuscular disease expert David Walk, M.D., Director of the multidisciplinary CMT and ALS clinics at the University of Minnesota Medical Center Fairview, and Acceleron management, and will take place on Monday, April 3, 2017 at 11:00 a.m. EDT. Conference Call and Webinar Details Date: Monday, April 3, 2017 Time: 11:00 a.m. (EDT) Participants can access the live conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and refer to the Acceleron CMT Webinar. The live webinar can be accessed on the Investors page of the Company's website at . A replay of the webinar will be available approximately two hours after the event on the Acceleron website. About ACE-083 ACE-083 is a therapeutic candidate that acts as a ligand trap for members in the transforming growth factor-beta (TGF-ß) superfamily involved in the regulation of muscle mass and strength. ACE-083 has been designed to increase muscle mass and strength selectively in the muscles into which the drug is administered. Acceleron is developing ACE-083 for diseases such as facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease in which improved muscle strength in target muscles may provide a clinical benefit. About Charcot-Marie-Tooth Disease (CMT) CMT is one of the most common inherited neurologic diseases estimated to affect more than 125,000 people in the United States. The primary clinical manifestations of CMT include muscle weakness in the lower legs and arms. The lower leg muscle weakness can result in foot drop and a high-stepped gait leading to frequent tripping or falls. The disease is typically diagnosed by the presence of a characteristic pattern of muscle weakness and other clinical signs and symptoms, as well as through genetic testing. There are no FDA approved drug therapies for CMT. About Acceleron Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases. For more information, please visit . Follow Acceleron on social media: @AcceleronPharma and LinkedIn. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements about the Company's strategy, future plans and prospects, including statements regarding the development of the Company's compound ACE-083, the timeline for clinical development and regulatory approval of the ACE-083, the expected timing for the reporting of data from ongoing trials, and the structure of the Company's planned or pending clinical trials. The words "anticipate," "appear," "believe," "continue," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks that preclinical testing of the Company's compounds and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that data may not be available when the Company expects it to be, that the Company will be unable to successfully complete the clinical development of the Company's compounds, that the development of the Company's compounds will take longer or cost more than planned, that the Company may be delayed in initiating, enrolling or completing any clinical trials, and that the Company's compounds will not receive regulatory approval or become commercially successful products. Other risks and uncertainties include those identified under the heading "Risk Factors" included in the Company's Annual Report on Form 10-K which was filed with the Securities and Exchange Commission (SEC) on March 1, 2017, and other filings that the Company has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect the Company's current views with respect to future events, and the Company does not undertake and specifically disclaims any obligation to update any forward-looking statements. Acceleron Pharma Inc.Todd James, IRC, 617-649-9393Senior Director, Investor Relations and Corporate CommunicationsorMedia:BMC CommunicationsBrad Miles, 646-513-3125